Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of Sorafenib-Pazopanib versus Pazopanib-Sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II). 15. Januar 2018 Retz, M., Bedke, J., Herrmann, E., Grimm, M., Zimmermann, U., Müller, L., Leiber, C., Teber, D., Wirth, M., Bolenz, C., van Alphen, R., De Santis, M., Beeker, A., Frank, M., Gschwend, J., 2017. Ann Oncol 28 (Supplement 5)(8450), v295–v329. doi:10.1093/annonc/mdx371 Abstract Interim Results from PAZOREAL: A Non-interventional Study to Assess Effectiveness and Safety of Pazopanib and Everolimus in the Changine mRCC Treatment Landscape. Bedke, J., Welslau, M., Boegemann, M., Schostak, M., Hering-Schubert, C., Petzoldt, A., Wolf, T., Schleicher, J., Doehn, C., Grüllich, C., Grünwald, V., Steiner, T., Ehness,… Weiterlesen Overall survival and quality of life in patients with metastatic breast cancer treated with nab-paclitaxel: Final results of the non-interventinal study NABUCCO. Potthoff, K., Nusch, A., Söling, U., Hansen, R., Salat, C., Grebhart, S., Harde, J., Marschner, N., 2017. Ann Oncol 28 (Supplement 5)(293P), 97. doi:10.1093/annonc/mdx365… Weiterlesen